Document:

Exhibit
10.2

 

The securities represented by this
certificate have not been registered under the Securities Act of 1933, as
amended, or registered or qualified under any state securities laws.  The securities may not be sold, transferred,
pledged or hypothecated unless such sale, transfer, pledge or hypothecation is
in accordance with such Act and applicable state securities laws.

 

WARRANT
NO.     

 

to Purchase
Common Stock of

 

GENAISSANCE
PHARMACEUTICALS, INC.

 

THIS WARRANT IS TO CERTIFY THAT                  ,
a                  
corporation (the “Holder”), is entitled to purchase from Genaissance
Pharmaceuticals, Inc., a Delaware corporation (the “Company”),             
shares of Common Stock of the Company (the “Common Stock”) for the
Exercise Price described herein upon the terms and conditions set forth
herein.  This warrant is being issued by
the Company in connection with the closing of a sale to the Holder of                 
shares of Common Stock and is one of a series of common stock purchase warrants
(collectively, the “November 2004 Warrants”) issued in connection with the
sale by the Company of up to approximately $6.0 million worth of Common Stock.

 

Section 1.  Certain Definitions.

 

(a) Unless otherwise stated in this Warrant, capitalized terms used but
not defined herein shall have the meanings set forth in that certain Securities
Purchase Agreement, dated as of the date hereof, between the Company and the
Holder.

 

(b) As used in this Warrant, capitalized terms used herein shall have
the following meanings:

 

“Expiration Date” shall mean November 19, 2009.

 

“Securities Act”
shall mean the Securities Act of 1933, as amended.

 

“Warrant” shall mean this Warrant and any warrant(s) issued in
substitution for this Warrant.

 

“Warrantholder” shall mean the Holder, as the initial holder of
this Warrant, and any Affiliate of the Holder to whom
this Warrant has been transferred in accordance with Section 10 hereof.

 

Section 2.  Warrant
Shares; Exercise Price.

 

(a) This Warrant may be exercised in accordance with Section 3
for up to             
shares of Common Stock (such shares, as may be adjusted from time to time
pursuant to Section 4, are referred to herein as the “Warrant
Shares”).

 

(b) The exercise price for each Warrant Share is $1.69
(such price, as may be adjusted from time to time pursuant to Section 4,
is referred to herein as the “Exercise Price”).

 

 

Section 3.  Exercise of Warrant.

 

(a)(i) Subject to Sections 3(b) and clause 3(a)(ii) below, the
Warrantholder may exercise this Warrant, in whole but not in part, at any time
beginning on the date hereof until and including the Expiration Date; provided,
however, that the minimum number of Warrants Shares subject to any
exercise notice shall be 25,000.  In the
event this Warrant is exercised in part, the Company, at its expense, will
cause to be issued in the name of, and delivered to, the Holder a new warrant
or warrants (dated the date hereof) of like tenor, calling in the aggregate on
the face or faces thereof for the number of Warrant Shares equal (without
giving effect to any adjustment therein) to the number of such shares called
for on the face of this Warrant minus the number of Warrant Shares for which
this Warrant was so exercised.

 

(a)(ii)  Notwithstanding
the foregoing, if at any time after one
year from the date of the issuance of this Warrant, and only after such time, a
registration statement on Form S-3 to enable the resale of all of the Warrant
Shares has not been declared effective by the Securities and Exchange
Commission, the Holder may, at its option, elect to exchange this Warrant, in
whole but not in part (a “Warrant Exchange”), into the number of Warrant Shares
determined in accordance with this Section 3(a)(ii) by presentation and
surrender of this Warrant to the Company at its principal office, accompanied
by a notice (a “Notice of Exchange”) stating that this Warrant is being
exchanged and the number of shares of Common Stock to be exchanged.  In connection with any Warrant Exchange, this
Warrant shall represent the right to acquire the number of shares of Common
Stock (rounded to the nearest whole number) equal to (i) the total number of
Warrant Shares (the “Total Number”), less (ii) the number of shares equal to
the quotient obtained by dividing (A) the product of the Total Number and the
then applicable Exercise Price by (B) the then fair market value (determined as
set forth below) per share of Common Stock. 
For purposes of this Section 3(a)(ii), the
“fair market value” per share of Common Stock as of any date shall be the closing
sale prices of the Common Stock, as reported on the securities exchange which
is the principal market for the Common Stock on the trading day immediately
preceding the date the Notice of Exchange is received by the Company.  If the Common Stock is not publicly traded,
the “fair market value” per share of Common Stock shall be an amount determined
by the Company’s Board of Directors upon request of the Holder.

 

(b) Except as provided in Section 3(a)(ii) above, the
Warrantholder shall exercise this Warrant by delivering to the Company at the
address set forth on the signature page hereto (i) the Exercise Notice set out
at the end of this Warrant, (ii) this Warrant and (iii) a cash payment equal to
the aggregate Exercise Price payable in respect of the number of Warrant Shares
purchased upon such exercise, by wire transfer to an account of the Company
designated in writing by the Company to the Warrantholder.

 

(c) Upon exercise of this Warrant and delivery of the Exercise Notice
with proper payment (or a valid Warrant Exercise pursuant to Section 3(a)(ii) above) relating thereto, the Company shall issue and
deliver as soon as practicable (and in any case within four (4) Business Days
thereafter) to the Warrantholder a stock certificate or certificates, duly
executed by the Company, representing the Warrant Shares.

 

(d) The stock certificate or certificates for the Warrant Shares to be
delivered in accordance with this Section 3 shall be registered in
the name of the Warrantholder or such other 

 

2

 

Person as shall be designated in the Exercise Notice.  Such certificate or certificates shall be
deemed to have been issued and the Warrantholder or any other Person so
designated to be named therein shall be deemed to have become the holder of
record of such shares, including to the extent permitted by law the right to
vote such shares or to consent or to receive notice as stockholders, as of the
time said notice is delivered to the Company as aforesaid.

 

(e) The Company shall pay all expenses payable in connection with the
preparation, issue and delivery of stock certificates under this Section 3,
including any transfer taxes resulting from the exercise of this Warrant by the
Holder and the issuance of the Warrant Shares to the Holder hereunder.

 

(f) Upon the exercise of this Warrant in accordance with the terms
hereof, the Warrant Shares shall be validly issued, fully paid and
non-assessable, and free from all liens, other than liens created by the
Warrantholder.

 

Section 4.  Adjustment of Exercise Price and Warrant Shares.

 

(a) If, at any time prior to the Expiration Date, the number of
outstanding shares of Common Stock is (i) increased by a stock dividend payable
in shares of Common Stock or by a subdivision or split-up of shares of Common
Stock or (ii) decreased by a combination of shares of Common Stock, then,
following the record date fixed for the determination of holders of Common
Stock entitled to receive the benefits of such stock dividend, subdivision, split-up,
or combination, the Exercise Price shall be adjusted to a new amount equal to
the product of (I) the Exercise Price in effect on such record date and (II)
the quotient obtained by dividing (x) the number of shares of Common Stock
outstanding on such record date (without giving effect to the event referred to
in the foregoing clause (i) or (ii)), by (y) the number of shares of Common
Stock which would be outstanding immediately after the event referred to in the
foregoing clause (i) or (ii), if such event had occurred immediately following
such record date.

 

(b) Upon each adjustment of the Exercise Price as provided in Section 4(a),
the Warrantholder shall thereafter be entitled to purchase, at the Exercise
Price resulting from such adjustment, the number of shares of Common Stock
equal to the product of (i) the number of shares of Common Stock that the
Warrantholder was entitled to purchase prior to such adjustment and (ii) the
quotient obtained by dividing (x) the Exercise Price existing prior to such
adjustment by (y) the new Exercise Price resulting from such adjustment.

 

Section 5.  Reclassification,
Etc.  In case of any reclassification
or change of the outstanding shares of Common Stock (other than as a result of
a subdivision, combination or stock dividend), or in case of any consolidation
of the Company with, or merger of the Company into, another corporation or
other business organization (other than a consolidation or merger in which the
Company is the continuing corporation and which does not result in any
reclassification or material change of the outstanding shares of Common Stock)
at any time prior to the Expiration Date, then, as a condition of such
reclassification, reorganization, change, consolidation or merger, lawful
provision shall be made, and duly executed documents evidencing the same from
the Company or its successor shall be delivered to the Warrantholder, so that
the Warrantholder shall have the right prior to the Expiration Date to
purchase, at a price not to exceed the aggregate Exercise Price, the kind and
amount of shares of stock and other 

 

3

 

securities and property
receivable upon such reclassification, reorganization, change, consolidation or
merger by a holder of the number of shares of Common Stock purchasable by the
Warrantholder immediately prior to such reclassification, reorganization,
change, consolidation or merger, and in any such case appropriate provisions
shall be made with respect to the rights and interests of the Warrantholder to
the end that the provisions hereof shall thereafter be applicable in relation
to any shares of stock and other securities and property thereafter deliverable
upon exercise hereof.

 

Section 6.  Reservation and Authorization of Common Stock.  The Company shall at all times reserve and
keep available for issuance such number of its authorized but unissued shares
of Common Stock as will be sufficient to permit the exercise of this Warrant.

 

Section 7.  Stock Books. 
The Company will not at any time, except upon dissolution, liquidation
or winding up or in accordance with Section 5, close its stock
books so as to result in preventing or delaying the exercise of this Warrant
during normal business hours.

 

Section 8.  Limitation of Liability.  No provisions hereof, in the absence of
affirmative action by the Warrantholder to purchase the Warrant Shares
hereunder, shall give rise to any liability of the Warrantholder to pay the
Exercise Price or as a stockholder of the Company (whether such liability is
asserted by the Company or creditors of the Company).

 

Section 9.  Legend. Each stock certificate representing Warrant
Shares shall bear a legend substantially in the following form:

 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER APPLICABLE
STATE SECURITIES LAWS, AND MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE
TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION UNDER THE ACT OR IN A
TRANSACTION WHICH QUALIFIES AS AN EXEMPT TRANSACTION UNDER THE ACT, THE RULES
AND REGULATIONS PROMULGATED THEREUNDER AND THE SECURITIES LAW OF ANY APPLICABLE
STATE.”

 

Section 10.  Transfer. 
Subject to compliance with the Securities Act and the applicable rules
and regulations promulgated thereunder, the Holder may transfer this Warrant,
in whole but not in part, to any of its affiliates without the consent of the
Company.  Any such transfer shall be made
at the office or agency of the Company at which this Warrant is exercisable, by
the registered holder hereof in person or by its duly authorized attorney, upon
surrender of this Warrant together with the assignment hereof properly
endorsed, and promptly thereafter a new warrant shall be issued and delivered
by the Company, registered in the name of the assignee.  Until registration of transfer hereof on the
books of the Company, the Company may treat the Holder as the owner hereof for
all purposes.

 

Section 11.  Loss, Destruction, Etc. of Warrant.  Upon receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of any such mutilation, upon surrender and
cancellation of this Warrant, the Company will make and deliver, in lieu of
such lost, stolen, destroyed or mutilated Warrant, 

 

4

 

a
new warrant of like tenor and representing the right to purchase the Warrant
Shares.

 

Section 12.  Amendments. 
The terms of this Warrant may be amended, and the observance of any term
herein may be waived (either generally or in a particular instance and either
retroactively or prospectively), upon written consent of the Company and the
holders of at least 50% of the shares of Common Stock issued or issuable upon
exercise of the November 2004 Warrants then outstanding; provided, however,
that any such amendment or waiver will apply to all November 2004 Warrants
then outstanding; and provided  further that the number of Warrant
Shares subject to this Warrant and the Exercise Price of this Warrant may not
be amended, and the right to exercise this Warrant may not be waived, without
the written consent of the holder of this Warrant (it being agreed that an
event occurring under any of the provisions of Section 4 or Section 5
of this Warrant shall not be considered an amendment of the number of Warrant
Shares or the Exercise Price).

 

Section 13.  Notices.  All
notices or other communications required or permitted hereunder shall be in
writing and shall be deemed given or delivered (a) when delivered personally,
(b) if transmitted by facsimile when confirmation of transmission is received,
(c) if sent by registered or certified mail, postage prepaid, return receipt
requested, three Business Days after mailing or (d) if sent by reputable
overnight courier service, one Business Day after delivery to such service; and
shall be addressed as follows:

 

	
  If
  to the Company, to:

  	
   

  	
  with a copy to:

  
	
   

  	
   

  	
   

  
	
  Genaissance
  Pharmaceuticals, Inc.

  Five Science Park

  New Haven, Connecticut 06511

  Attention: Chief Financial Officer

  Facsimile: (203) 786-3567

  	
   

  	
  Wilmer Cutler Pickering
  Hale and Dorr LLP

  60 State Street

  Boston, Massachusetts 02109

  Attention: Steven D. Singer, Esq.

  Facsimile: (617) 526-5000

  
	
   

  	
   

  	
   

  
	
  If
  to the Holder, to:

  	
   

  	
  with a copy to:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Attention:
  

  	
   

  	
  Attention: 

  
	
  Facsimile:

  	
   

  	
  Facsimile:

  

 

Section 14.  Successors and Assigns.  This Warrant shall bind and inure to the
benefit of and be enforceable by the parties hereto and their respective
permitted successors and assigns.

 

Section 15.  Governing Law. 
This Warrant and the obligations arising hereunder shall be governed by,
and construed and enforced in accordance with, the laws of the State of New
York (other than its conflicts of law provisions).

 

5

 

Section 16.  No
Stockholder Rights With Respect to Warrant Shares.  Until the Warrant Shares subject to this
Warrant are issued to the Warrantholder upon exercise of this Warrant, the
Warrantholder shall have no right to vote the Warrant Shares in connection with
any matters to which holders of Common Stock are entitled to vote and shall
have no rights as a stockholder of the Company with respect to the Warrant
Shares.

 

[Signature page follows]

 

6

 

IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by a duly authorized officer as
of November 19, 2004.

 

	
   

  	
  GENAISSANCE PHARMACEUTICALS,

  INC., a Delaware corporation

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By: 

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  
	
   

  	
   

  	
  Title:

  
	
   

  	
   

  
	
   

  	
  Address:

  
	
   

  	
   

  
	
   

  	
  Five Science Park

  
	
   

  	
  New Haven, Connecticut
  06511

  
	
   

  	
  Attention: Chief
  Financial Officer

  
	
   

  	
  Fax: (203) 786-3567

  

 

[Holder’s agreement and acknowledgement follows]

 

 

Signature
Page to Warrant

 

 

	
  AGREED AND ACKNOWLEDGED

  	
   

  
	
  AS OF NOVEMBER    ,
  2004:

  	
   

  
	
   

  	
   

  
	
  [HOLDER],

  	
   

  
	
  a
                              
  corporation

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  

 

Holder’s
Agreement and Acknowledgement

 

 

EXERCISE
NOTICE

 

(to be executed only upon exercise of Warrant)

 

To:                              Genaissance
Pharmaceuticals, Inc.

Five Science Park

New Haven, Connecticut
06511

Attention:  Chief Financial Officer

 

The undersigned, pursuant to the provisions set forth in the attached
Warrant, hereby irrevocably elects to purchase                           
of the Warrant Shares covered by such Warrant and herewith makes payment of the
aggregate Exercise Price payable in respect of the number of Warrant Shares
purchased upon such exercise, as provided for in such Warrant.

 

The Warrant Shares shall be registered in the name of the following
Person:

 

                                                             .

 

	
  Dated: 

  	
   

  	
   

  	
  Name: 

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Signature: 

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Address:<PAGE>

                                                                   EXHIBIT 10.20

                       MedStrong International Corporation

                          STOCK OPTION AGREEMENT DATE:

November 16, 2004

Optionee: Jeanine Marie Folz

Option to Purchase Aggregate Number of Shares:                250,000
Price Per Share:                                              $.05
Date of Grant:                                                November 16, 2004

         1. MedStrong International Corporation (the "Company"), deeming it in
its best interest that you continue to provide services to the Company, and as
an incentive for you to do so and to give you an increasing interest in the
Company as stockholder, hereby gives and grants you the right and option to
purchase up to the aggregate number of shares set forth above of the Company's
common stock, par value $.001 per share (the "Common Stock"), at the price per
share also set forth above (the "Options"). The per share purchase price is not
less than the fair market value per share of Common Stock on the date the grant
of the Options was approved by the Board of Directors (the "Date of Grant").

         2. The Options are exercisable immediately. The Options shall expire on
the date ten (10) years after they become exercisable, the date which has been
specified by the Board of Directors, and shall not be exercisable after their
expiration date.

         3. The Options are exercisable only by you and are not transferable by
you, other than by will or by the laws of descent and distribution. In the event
of your death, the Options may be exercised by the estate, personal
representative or beneficiary who has acquired the right to exercise the Options
by bequest or inheritance or by the reason of your death, and then only if, and
to the extent that, you were entitled to exercise the Options at the date of
your death, up to the maximum exercise period of one (1) year.

         4. The Options (or any part of installment thereof) must be exercised
by giving written notice to the Company's Chief Executive Officer at its
principal office address, or to such transfer agent as the Company's Chief
Executive Officer shall designate. The notice, the form of which is attached
hereto as Exhibit A, must specify the date of the notice, the number of shares
as to which the Options are being exercised and the expected date of such
purchase (which, unless the Company otherwise consents, shall be at least five
(5) days and not more than fifteen (15) days after the date you mail the
notice). The notice must be accompanied by the tender of payment of the purchase
price for the number of shares specified in the notice. Payment must be made (a)
in cash, or (b) by certified check, or (c) with previously acquired Common Stock
of the Company having a fair market value equal to the purchase price of the
shares being purchased, or (d) any combination thereof, or (e) any other method
approved by the Board of Directors in its discretion. If the Board of Directors
exercise its discretion to permit payment by means other than the methods set
forth in clauses (a), (b), (c) or (d), such discretion must be exercised in
writing prior to the time you exercise the Options.

                                       32
<PAGE>

         5. Upon payment of the purchase price of the shares specified in the
notice, the Company shall deliver to you certificates for the shares purchased.
The holder of the Options shall not have the rights of a shareholder with
respect to the shares covered by the Options until the date of the stock
certificates issued to the holder for such shares.

         6. You may be required to make an appropriate representation at the
time of any exercise of the Options that it is your intention to acquire the
shares being purchased for investment and not for resale or distribution. In
addition, you may be required to agree in writing not to sell any shares
acquired pursuant to the Options or any other shares of the Company that you may
now or hereafter acquire except either (a) in compliance with the Securities Act
of 1933, as amended, provided that the Company shall be under no obligation to
register either the Plan or any securities obtained pursuant to your exercise of
your rights, hereunder, with the Securities and Exchange Commission, or (b) with
prior written approval of the Company. An appropriate legend restricting the
sale of the shares may be placed upon the certificates representing the shares
and any resale must be in compliance with the Securities Act of 1933, as
amended, and the rules and regulations thereunder.

           7. This agreement shall be binding upon and shall inure to the
benefit of any successors or assigns of the Company, and, to the extent herein
provided, shall be binding upon and inure to the benefit of your legal
representatives.

         8. The Option is not, and should not be deemed to be, an employment
agreement between you and the Company, and nothing contained herein shall be
deemed to confer upon you any right to remain in the employ of the Company or
any subsidiary thereof, or in any way to limit the right of the Company or any
such subsidiary to terminate your employment.

         9. If the foregoing is in accordance with your understanding and
approved by you, please so confirm by signing and returning the duplicate of
this letter enclosed for that purpose.

                                    Very truly yours,

                                    MEDSTRONG INTERNATIONAL CORPORATION

                                              /s/ Jeanine Folz
Date: November 16, 2004             By: ________________________________

     I hereby confirm that the foregoing is in accordance with my understanding
     and is hereby agreed and accepted in its entirety as of the date of the
     above letter.

                  /s/ Jeanine Folz
By: ______________________________________
    NAME

           November 16, 2004
Date: _______________________________

                                       33
<PAGE>

                                    Exhibit A

Form of Exercise Notice

MedStrong International Corporation                Date: _______________________
350 Bedford Street, Suite 203
Stamford, CT 06901
Attention: Chief Executive Officer

The undersigned hereby: (1) irrevocably subscribes for and offers to purchase
__________________ of common stock of MedStrong International Corporation
pursuant to, and in exercise of, the options granted to the undersigned on
_________________; and (2) encloses payment of _______________________
($_________) for these shares at a purchase price of $_________ per share.

The shares should be issued be issued in the name of ___________________________
and should delivered to such holder at:

________________________________________________________________________________

________________________________________________________________________________

________________________________________________________________________________
                                [insert address]

Signature: _____________________________________________________________________

Print Name: ____________________________________________________________________

Social Security Number:  _______________________________________________________

                                       34

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]